Immunohistochemical phenotype of colorectal carcinoma in patients with KRAS mutation and mismatch repair status

Desislava Tashkova; Nevena Ilieva; Denitsa Serteva; Yana Feodorova; Nikolay Mehterov; Angelina Mollova; Svitlana Bachurska

doi:10.3897/folmed.65.e81334

Immunohistochemical phenotype of colorectal carcinoma in patients with KRAS mutation and mismatch repair status

Folia Med (Plovdiv). 2023 Jun 30;65(3):378-383. doi: 10.3897/folmed.65.e81334.

Authors

Desislava Tashkova¹, Nevena Ilieva¹, Denitsa Serteva¹, Yana Feodorova¹, Nikolay Mehterov¹, Angelina Mollova², Svitlana Bachurska³

Affiliations

¹ Medical University of Plovdiv, Plovdiv, Bulgaria.
² St George University Hospital, Plovdiv, Bulgaria.
³ National Oncology Hospital, Sofia, Bulgaria.

PMID: 38351812
DOI: 10.3897/folmed.65.e81334

Abstract

Aberrant expression of CK7/CK20/CDX2 is reported in percentage of colorectal carcinomas (CRC).

Keywords: colorectal carcinoma CRC MSI KRAS.

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

MeSH terms

Biomarkers, Tumor / genetics
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / pathology
DNA Mismatch Repair / genetics
Humans
Keratin-20 / genetics
Keratin-20 / metabolism
Mutation
Phenotype
Proto-Oncogene Proteins p21(ras)* / genetics
Proto-Oncogene Proteins p21(ras)* / metabolism

Substances

Proto-Oncogene Proteins p21(ras)
Keratin-20
Biomarkers, Tumor
KRAS protein, human